News & Updates
Filter by Specialty:
Psilocybin shows promise in relieving depression in cancer patients
The 5-HT2A receptor agonist psilocybin, when taken under medical supervision, may offer a promising approach to treatment of major depressive disorder (MDD) in cancer patients, results of a small phase II study suggest.
Psilocybin shows promise in relieving depression in cancer patients
08 May 2023
Second primary melanoma tied to better survival than single primary lesion
Patients who present with second primary melanomas have better survival and thinner lesions than those presenting with single primary melanomas, reveals a study.
Second primary melanoma tied to better survival than single primary lesion
06 May 2023
Immune-related AEs predict survival in cancer patients on ICI
Developing cutaneous immune-related adverse events (cirAEs) among advanced cancer patients on immune checkpoint inhibitor (ICI) appears to be a sign of longer overall survival, particularly in those with melanoma, suggests a recent study.
Immune-related AEs predict survival in cancer patients on ICI
05 May 2023
Surgery, but not chemo, may benefit patients with rare ovarian neoplasms
Good quality surgery conferred a progression-free survival (PFS) benefit for women with ovarian sex cord stromal tumours (SCST) in the first-line setting and on first and second relapse. Chemotherapy, on the other hand, had no impact on survival in the first-line or relapse setting.
Surgery, but not chemo, may benefit patients with rare ovarian neoplasms
05 May 2023
Immune-related AEs tied to improved survival in bladder cancer patients on atezolizumab
In patients with locally advanced or metastatic urothelial cancer patients receiving atezolizumab treatment, immune-related adverse events (AEs) were associated with improved survival outcomes, according to an analysis of individual participant data from the IMvigor210 and IMvigor211 studies.
